Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that ER positive, HER2-negative, and PR positive status confers therapeutic sensitivity to Letrozole, Ribociclib in patients with Invasive Breast Carcinoma.
Health Canada approved ribociclib, in combination with an aromatase inhibitor, for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.
This statement is based on a regulatory approval from the Health Canada:
KISQALI (ribociclib tablets) is indicated, in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, or men ,with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.